Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

Endocrine treatment plus CDK4/6 inhibitors have become standard of care for estrogen receptor positive (ER+) breast cancer. Although immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in a variety of cancer types, only limited success has been achieved for metastatic breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rong, Yang, Yuchen, Ye, Wei-Wu, Xiang, Jianxing, Chen, Songan, Zou, Wei-Bin, Wang, Xiao-Jia, Chen, Tianhui, Cao, Wen-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900143/
https://www.ncbi.nlm.nih.gov/pubmed/33634015
http://dx.doi.org/10.3389/fonc.2020.588080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900143/
https://www.ncbi.nlm.nih.gov/pubmed/33634015
http://dx.doi.org/10.3389/fonc.2020.588080

Ejemplares similares